Nama's AI scorecard currently rates LifeStance Health Group Hold (5.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is LFST's P/E ratio?

LifeStance Health Group trades at a trailing price-to-earnings ratio of 36.2.

When does LFST report earnings?

LifeStance Health Group's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.09.

What is the LFST price target?

The median analyst price target from 10 analysts is $15.00, with a range of $12.00 – $18.00.

Is LFST Shariah compliant?

Nama's AAOIFI-style screen reads LifeStance Health Group as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

LifeStance Health Group (LFST)

Healthcare · Medical Care Facilities · NASDAQ

LifeStance Health Group (LFST) is a Healthcare company in the Medical Care Facilities industry. It has a market capitalization of $5.23B, a trailing price-to-earnings ratio of 36.2 and a free-cash-flow yield of 2.0%. Over the most recent reported fiscal year, revenue grew 13.8% and free cash flow per share grew 24.5%. Nama's AI scorecard rates it Hold, 5.6 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Hold · 5.6/10

The sections balance. As of Nov 7, 2026.

Momentum

Leading · +93.8% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-12.1%

How far the last close sits under the highest price of the past five years.

Market cap	$5.23B
Trailing P/E	36.2
Price / book	3.6
Price / sales	3.3
FCF yield	2.0%
Dividend yield	—
Gross margin	33.6%
Operating margin	5.0%
Net margin	3.2%
Revenue growth (YoY)	+13.8%
Revenue growth (3-yr annual)	+18.3%
EPS growth (YoY)	—
FCF/share growth (YoY)	+24.5%
Beta	1.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Care Facilities

LFST earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $0.09). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$0.11	$0.08	+37.5%	—
Q2 2026	Aug 6, 2026	$0.11	$0.08	+37.5%	$435.35M
Q1 2026	May 7, 2026	$0.07	$0.06	+16.7%	$403.48M
Q4 2025	Feb 25, 2026	$0.09	$0.05	+80.0%	$382.19M

LFST analyst price target

Median target $15.00 from 10 analysts, ranging $12.00 – $18.00.

Medical Care Facilities peers

Ticker	Company	Market cap	P/E
HCA	HCA Healthcare	$103.40B	16.5
THC	Tenet Healthcare	$22.55B	12.7
EHC	Encompass Health	$13.50B	22.4
FMS	Fresenius Medical Care	$12.15B	10.2
DVA	DaVita	$12.04B	13.6
UHS	Universal Health Services	$11.52B	8.6
ENSG	Ensign Group	$10.56B	23.8
PACS	PACS Group	$7.87B	20.1

Explore live LFST data on Nama Insights →

LFST FAQ

Is LFST a buy?: Nama's AI scorecard currently rates LifeStance Health Group Hold (5.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is LFST's P/E ratio?: LifeStance Health Group trades at a trailing price-to-earnings ratio of 36.2.
When does LFST report earnings?: LifeStance Health Group's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.09.
What is the LFST price target?: The median analyst price target from 10 analysts is $15.00, with a range of $12.00 – $18.00.
Is LFST Shariah compliant?: Nama's AAOIFI-style screen reads LifeStance Health Group as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.